Last reviewed · How we verify
LOKELMA 5 GM Powder for Oral Suspension
LOKELMA 5 GM Powder for Oral Suspension is a Potassium binder Small molecule drug developed by Steno Diabetes Center Copenhagen. It is currently FDA-approved for Hyperkalemia (elevated serum potassium levels).
Lokelma (sodium zirconium cyclosilicate) is a potassium binder that traps potassium in the gastrointestinal tract and increases fecal potassium excretion.
Lokelma (sodium zirconium cyclosilicate) is a potassium binder that traps potassium in the gastrointestinal tract and increases fecal potassium excretion. Used for Hyperkalemia (elevated serum potassium levels).
At a glance
| Generic name | LOKELMA 5 GM Powder for Oral Suspension |
|---|---|
| Sponsor | Steno Diabetes Center Copenhagen |
| Drug class | Potassium binder |
| Target | Potassium ion (K+) in gastrointestinal tract |
| Modality | Small molecule |
| Therapeutic area | Nephrology / Cardiology |
| Phase | FDA-approved |
Mechanism of action
Lokelma is a non-absorbed, selective potassium binder that works in the distal colon by exchanging sodium and hydrogen ions for potassium ions, thereby reducing serum potassium levels. It is designed to treat hyperkalemia by removing potassium from the body through the feces without systemic absorption, making it suitable for chronic management of elevated potassium levels.
Approved indications
- Hyperkalemia (elevated serum potassium levels)
Common side effects
- Constipation
- Nausea
- Abdominal discomfort
- Diarrhea
Key clinical trials
- A Prospective, Randomized, Open-Label, Cross-Over Study of Lokelma to Control Interdialytic Hyperkalemia (PHASE4)
- The Effect of Sodium Zirconium Cyclosilicate on Albuminuria in Patients With Type 2 Diabetes and Hyperkalemia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LOKELMA 5 GM Powder for Oral Suspension CI brief — competitive landscape report
- LOKELMA 5 GM Powder for Oral Suspension updates RSS · CI watch RSS
- Steno Diabetes Center Copenhagen portfolio CI
Frequently asked questions about LOKELMA 5 GM Powder for Oral Suspension
What is LOKELMA 5 GM Powder for Oral Suspension?
How does LOKELMA 5 GM Powder for Oral Suspension work?
What is LOKELMA 5 GM Powder for Oral Suspension used for?
Who makes LOKELMA 5 GM Powder for Oral Suspension?
What drug class is LOKELMA 5 GM Powder for Oral Suspension in?
What development phase is LOKELMA 5 GM Powder for Oral Suspension in?
What are the side effects of LOKELMA 5 GM Powder for Oral Suspension?
What does LOKELMA 5 GM Powder for Oral Suspension target?
Related
- Drug class: All Potassium binder drugs
- Target: All drugs targeting Potassium ion (K+) in gastrointestinal tract
- Manufacturer: Steno Diabetes Center Copenhagen — full pipeline
- Therapeutic area: All drugs in Nephrology / Cardiology
- Indication: Drugs for Hyperkalemia (elevated serum potassium levels)
- Compare: LOKELMA 5 GM Powder for Oral Suspension vs similar drugs
- Pricing: LOKELMA 5 GM Powder for Oral Suspension cost, discount & access